NCT06999252View on ClinicalTrials.gov

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

June 1, 2029

Conditions
Colon Cancer
Interventions
DRUG

Rimegepant

Take 75 mg every other day

DRUG

PD-1

200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER